Abstract
Balloon-expandable and self-expanding transcatheter aortic valve replacement (TAVR) devices are FDA approved and have been equally efficacious in treatment of severe aortic stenosis. However, long-term durability of these TAVR devices are unknown and durability is dependent upon valve design, in
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
